BerGenBio ASA reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was NOK 70.5 million compared to NOK 67.32 million a year ago. Basic loss per share from continuing operations was NOK 0.8 compared to NOK 0.77 a year ago. For the nine months, net loss was NOK 240.6 million compared to NOK 183.16 million a year ago. Basic loss per share from continuing operations was NOK 2.74 compared to NOK 2.51 a year ago.